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Viral load measurements. Viral RNA was amplified and quantified as described 7 previously [23] . Briefly, RNA was manually extracted from fluid samples (CSF or blood 8 serum) using the High Pure Viral RNA Kit (Roche). RNA was then subjected to reverse 9 transcription and quantitative PCR using primers and a fluorescently conjugated probe 10 on an Applied Biosystems 7900 instrument.
12

Plaque Reduction Neutralization Test (PRNT) 80 measurements. Neutralizing antibody
13
quantification by plaque reduction neutralization test (PRNT) endpoint 80% PRNT titers 14 were determined in infant macaque plasma, where each sample was tested in duplicate.
15
Plasma samples were heated to 56°C for 30 minutes to inactivate complement, serially (represented as the mean final virus-serum dilution from both replicates) that inhibited at 1 least 80% of plaques is reported as the antibody titer.
3
Detection of ZIKV-specific IgG in rhesus plasma. High-binding 96-well ELISA plates 4 (Greiner; Monroe, NC) were coated with 40 ng/well of 4G2 monoclonal antibody, 5 produced in a mouse hybridoma cell line (D1-4G2-4-15,ATCC; Manassas, VA), diluted 6 to 0.8 ng/uL in 0.1M carbonate buffer (pH 9.6) and incubated overnight at 4°C. Plates 7 were blocked in 1X Tris-buffered saline containing 0.05% Tween-20 and 5% normal goat 8 serum for 1 hour at 37°C, followed by an incubation with diluted ZIKV (strain 9 PRVABC59, BEI; Manassas, VA) for 1 hour at 37°C. Optimal virus dilution was plus 2 x standard deviations (SD). For samples considered positive, their OD values for 23 the serial dilution were entered into Prism v8 (GraphPad Software; San Diego, CA) to transformed data was then analyzed using a sigmoidal dose-response nonlinear 1 regression model. Any sample considered negative was assigned an ED50 of 12.5, the 2 lowest dilution tested, because ED50 cannot be accurately calculated below the lowest 3 dilution tested. Zika-specific IgG binding was reported in Log10 ED50.
5
Behavioral observations. We employed a battery of age-appropriate behavioral tests that 6 are designed for use in infant nonhuman primates. These tests were performed to 7 identify any effects prenatal exposure to ZIKV. Both infants received neurobehavioral 8 tests modelled upon testing tools used for human infants [34, 35] 
25
F09 was the only animal in our studies to clear blood viral RNA prior to day 5. In infant F10, the viral load remained below 1,000 copies per milliliter but remained detectable 1 until day 7 ( Figure 3A ). These acute viral loads contrast with those of 11 pregnant 2 females infected with the same stock of the same strain of the virus at the same dose 3 and route ( Figure 3B ) as well as four non-pregnant females ( Figure 3C ) and four adult 4 males ( Figure 3D ) infected with a separate stock of the same dose and strain of the 5 virus. Area under the curve (AUC) analyses showed that F09 had a total viremia lower 6 than all other animals in our previous studies with the exception of a single pregnant 7 female that had a slightly lower peak viremia and cleared virus from blood far earlier 8 than was typical for our pregnant animals. F10 had total viremia far lower than any 9 animal in any cohort tested at our facilities ( Figure 3E ). At necropsy, we performed RT
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PCR for ZIKV RNA on serum, CSF, multiple brain regions (frontal cortex, parietal lobe, 11 occipital lobe, temporal lobe, brain stem, optic nerve, cerebellum, choroid plexus, and 12 subcortical white matter), and axillary lymph nodes and virus was detected only in the 13 axillary lymph in both animals ( Figure 3F ). These data contrast sharply from a recent 14 study that found infants born to healthy dams and infected postnatally showed viral loads status. Both our study and a published study [32] performed behavioral observations on cannot be directly compared. Nonetheless, behavioral data from our infants showed no 1 direct evidence of infection nor negative consequences of infection of their dams.
3
Both infants in our study harbored detectable levels of anti-ZIKV neutralizing antibodies 4 at birth that declined between one-and four-months post birth. We interpret these data 5 to suggest these antibodies were passively acquired from the dams as opposed to 6 mounted directly by the infants. ZIKV-binding IgG also declined after birth but remained 7 detectable between three and five months of age, when the animals were infected.
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When we infected the infants with ZIKV, they exhibited low peak viremia that was rapidly 
